Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colesevelam for major low anterior resection syndrome
ACTRN12620000755932Phase 4Not yet recruiting
- Sponsor
- University of Otago
- Start
- Sep 2020
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of colesevelam in low anterior resection syndrome (LARS) (2 arms), sponsored by University of Otago. Primary endpoints: Low Anterior Resection Syndrome score, Short Form-12 Health Survey and 1 more. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
colesevelam
03
Conditions
low anterior resection syndrome (LARS)
Beyond the preview
Go deeper on ACTRN12620000755932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000755932.